Related Experiment Video
Updated: Jul 12, 2025
07:52
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
20.6K
[Heart disease in hemodialysis: physiopathology and therapeutic breakthroughs]
Lucile Mercadal1, Jean-Jacques Boffa1,2, Jean-Philippe Collet3
1Hôpitaux Sorbonne Université, sites Pitié-Salpêtrière, Tenon, AP-HP, service de néphrologie, Paris, France
Nephrologie & Therapeutique
|November 2, 2023
Insights
Patients on hemodialysis face high cardiovascular risks. This review examines current trials and guidelines on cardiovascular therapies and coronary investigations for this vulnerable population.
Area of Science:
- Cardiology
- Nephrology
- Internal Medicine
Background:
- Patients undergoing hemodialysis exhibit a significantly higher risk of cardiovascular events and mortality.
- Current cardiovascular treatment strategies and diagnostic approaches for hemodialyzed individuals are often debated.
Purpose of the Study:
- To review and synthesize recent clinical trials and established guidelines concerning cardiovascular care in the hemodialysis population.
- To address controversies surrounding specific cardiovascular therapies and coronary investigations in this patient group.
Main Methods:
- Comprehensive literature search of recent cardiovascular trials.
- Analysis of current clinical practice guidelines relevant to hemodialyzed patients.
- Discussion of controversial aspects based on collected evidence.
Main Results:
- Identification of key trials and guidelines impacting cardiovascular care in hemodialysis.
- Highlighting areas of ongoing debate regarding treatment efficacy and diagnostic utility.
- Synthesis of evidence to inform clinical decision-making.
Conclusions:
- The management of cardiovascular disease in hemodialysis patients requires careful consideration of specific evidence.
- Further research and updated guidelines are needed to optimize therapies and investigations for this high-risk group.
Abstract:
Especially exposed to frequent cardiovascular events and its related mortality, some cardiovascular therapies of the hemodialyzed population as well as coronary investigations remain controversial. We have collected data and discussed recent trials and guidelines dedicated to this patient subset.
Related Concept Videos
01:25Hemodialysis I: Introduction
36
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
36
01:24Hemodialysis II: Procedure and Complications
26
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
26
01:22Heart Failure Drugs: Diuretics
400
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
400
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:25Hemodialysis III: Nursing Management
25
The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
25
01:27Dialysis
330
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
330